The 2026 Pre-IPO Biotech Stack
The biotech category in 2026 splits across five sub-stacks that increasingly share substrate with the AI-lab cluster. The first is generative-chemistry & protein-design: Insitro (Daphne Koller's $1.5B+ post-money venture with NASH and ALS programs), Profluent ($35M Series A led by Lux, protein-LM for gene-editing + therapeutics), and Cradle (~$60M Series A with J&J pharma partnership, protein-engineering foundation model). The second is AI-designed antibody therapeutics: BigHat Biosciences ($350M Series B 2024 led by a16z, ML-driven antibody design platform with Phase-1-ready antibody assets), and the publicly-traded Absci ($ABSI) and Exscientia ($EXAI) on the public anchor side. The third is foundation-model protein-language-model infra: EvolutionaryScale (a public foundation-model org founded by Alexander Rives in 2024 with $142M seed, ESM3 protein model with commercial licensing to pharma), and Meta's open-source ESM2 lineage that underpins much of the cohort. The fourth is computational bio platforms: Recursion ($RXRX public, RecOS platform across high-content imaging + ML + chemistry), Schrödinger ($SDGR public, physics-based molecular simulation), and Generate Biomedicines (private Flagship-incubated 2018, generative-biology platform). The fifth is synthetic biology and bio-manufacturing: Ginkgo Bioworks ($DNA public via 2021 SPAC, cell-engineering and organism-programming platform), Cellarity (Flagship Pioneering 2020, single-cell-omics driven small-molecule discovery), Dyno Therapeutics (private, $100M Series A 2020 with Bayer partnership on gene-therapy capsids), and Inceptive (private 2021, RNA biology foundation model).
The most-IPO-ready names in this category diverge by sub-stack. Insitro sits at the top of the AI-bio-native IPO queue: the company has $640M+ raised, multiple early-clinical-stage programs in NASH and ALS, a Daphne-Koller-led team with deep AI-bio credibility, and the Series-C round size implies the next primary round would be at $2B+ post-money (the natural inflection that maps to "S-1 plausibility"). BigHat Biosciences is a credible 2027 IPO candidate if any of its antibody-asset programs reach Phase-1 IND clearance — the asset-side upside of one Phase-2 readout would re-rate the $350M Series B mark to $1B+ post-money. Cradle and Profluent are at earlier stage but with strategic-acquirer appeal (Roche, Novartis, Eli Lilly have all done AI-bio partnership-plus-M&A plays historically). The publicly-traded names (Recursion, Schrödinger, Absci, Ginkgo Bioworks, Exscientia) all carry AI-bio crossover theses and have re-rated from 2023 troughs on the strength of pharma BD partnerships and pipeline progression.
The 2024–2025 funding-cycle dynamic for AI-bio follows the same pattern as AI dev-tools: valuations corrected sharply upward from 2023 trough levels on the strength of foundation-model platform plays, and several early-stage names that were facing "down-round or shut" risk in 2023 closed healthy Series As at 2024–2025 multiples. The structural difference between AI-bio and AI dev-tools is the asset-bottleneck: AI-bio companies' exit paths include pharma partnership-royalty monetization, asset out-licensing, and (rarely) Phase-2-readout-driven IPO — meaning the "exit multiple" of a $1.5B private Round C is meaningfully higher than the equivalent dev-tools private mark because of the asymmetric upside from a single clinical-readout event.
What changed in 2026
Three macro shifts define the AI-bio market in 2026. First, the public AI-bio cohort recovered meaningfully from the 2023 biotech-XBI-sector trough — Recursion ($RXRX), Schrödinger ($SDGR), Absci ($ABSI), Ginkgo Bioworks ($DNA), and Exscientia ($EXAI) all re-rated from 2023 lows on the strength of pharma BD partnerships and clinical-pipeline progression. Second, the pre-IPO AI-bio class crossed the threshold of "credible exit path" — Insitro's Series C at $1.5B+ post-money in 2024 mapped the cohort onto a forward path that resembles the AI-dev-tools S-1 pattern: foundation-model platform + clinic-ready assets + pharma BD partnerships + sizable primary round. Third, the protein-language-model sub-category emerged as a standalone investable stage with EvolutionaryScale (ESM3), Profluent (ProGen2), Cradle (protein design), and BigHat (antibody design) all converging on the same compute substrate (large GPU clusters for transformer training) the AI labs use. The companies in this sub-category compete with the AI-lab cohort for the same technical talent (ML researchers with biology backgrounds) and the same infrastructure (Lambda Labs, CoreWeave, AWS capacity).
Why AI-bio is a 2026–2028 sector with public-market exits
The AI-bio category has three drivers that the public market rewards. First, the asset-side upside — one Phase-2 readout for a generative-chemistry-discovered molecule can be worth $1B+ to a $1.5B-mark pre-IPO anchor. The comparable for the dev-tools cohort is "ARR growth driving valuation," but for AI-bio it's "clinical-readout-event-driven valuation step-ups" — a fundamentally different return distribution that the public-market-IPO path accommodates because Phase-2 events are timed catalyst events. Second, the pharma BD revenue — every AI-bio company in this cohort has at least one upfront+milestone+royalty partnership with a tier-1 pharma company (Bayer, Roche, Novartis, Eli Lilly, J&J). Pharma BD economics anchor a software-like revenue base that smooths the asset-event volatility. Third, the platform-company strategic-acquirer list is wide — Roche, Novartis, Eli Lilly, Sanofi, Pfizer, J&J, Merck, GSK, Amgen, Vertex, Regeneron, and Bayer have all done AI-bio partnership-plus-M&A plays historically, and most have $1B+ M&A budget lines for AI-bio bolt-on acquisitions. This means even the early-stage names (Profluent, Cradle, EvolutionaryScale) have a credible exit that doesn't require an IPO path.
The clinical-trial economic model
The AI-bio pre-IPO class sits at the intersection of two economic models: the AI-lab compute-cohort model (compute substrate, foundation-model engineering, ML talent) and the biotech asset-development model (wet-lab research, IND filings, Phase-1/2/3 trials, pharma commercialization). The capital intensity is meaningfully higher than for the AI dev-tools class — a single Phase-2 trial can cost $30M-$80M, and a single Phase-3 trial can cost $200M-$400M. This is why multiple names in the cohort (BigHat, Cradle, Profluent, EvolutionaryScale, Dyno) are picking the platform-company-with-pharma-BD-monetization route over the proprietary-IND-development route — the platform economics are more IPO-friendly because the platform-business revenue scales with pharma-BD-event-count, not with single-asset-trial outcomes.
Pre-IPO access
Accredited investors can access most pre-IPO AI-bio names via secondary-market partners. Hiive carries the deepest inventory of Insitro paper following the Series-C valuation print, with select inventory of Cradle, BigHat, and Profluent paper. Forge Global lists the broader pool — BigHat, EvolutionaryScale, and Dyno Therapeutics round out the longer tail. EquityZen is a third venue. Minimum investments typically $10K–$25K. Retail investors gain direct exposure via the publicly-traded anchors: Recursion ($RXRX), Schrödinger ($SDGR), Ginkgo Bioworks ($DNA), Absci ($ABSI), and Exscientia ($EXAI) trade on US exchanges with retail-accessible liquidity. Indirect proxies include Illumina ($ILMN) for sequencing-infrastructure and Tempus AI ($TEM) for AI-clinical-genomics.
Get pre-IPO AI-bio exposure
TechStackIPO routes accredited investors to vetted secondary-market partners for every name in this stack. Hiive carries Insitro with the deepest inventory; Forge Global covers BigHat, EvolutionaryScale, and the broader AI-bio private market.
Open Hiive → Open Forge →Affiliate disclosure: TechStackIPO earns a referral fee on completed transactions. See referral disclosure.
Disclaimer: Biotech pre-IPO valuations shown reflect last-known private rounds, secondary-market transactions, and public-market anchor marks — not formal IPO prices. Specific categories (and platform availability of each name on Hiive / Forge / EquityZen / Linqto) change monthly. References to clinical-pipeline stage, pharma BD partnerships, and asset-side economics are sourced from company press releases, ENDPOINTS NEWS citations, TechCrunch coverage, and TechStackIPO's AEO citation scan. This page is informational; not investment advice. See referral disclosure for affiliate details.